NEW YORK (GenomeWeb News) – Compugen said today that it will receive grants totaling around $500,000 from the Office of the Chief Scientist of Israel to fund the firm's drug and diagnostic product candidate discovery activities.

Tel Aviv, Israel-based Compugen said that it would use the grant money to discover additional drug targets for antibody therapeutics and preclinical nucleic acid biomarkers for drug-induced toxicity. The firm said these activities would be based on "modifying and enhancing" its 10 existing discovery platforms.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.